We have previously reported an array comparative genomic hybridization profile that identifies triplenegative breast cancers (TNBC), with BRCA1 dysfunction and a high sensitivity to intensified dose bifunctional alkylating agents. To determine the effect of conventional-dose chemotherapy in patients with this so-called BRCA1-like profile, clinical characteristics and survival were studied in a large group of TNBC patients.
introduction
The triple-negative breast cancer (TNBC) subtype occurs in ∼15% of cases and is associated with rapid growth, early metastasis and a worse prognosis than other breast cancer subtypes [1] . Since targeted treatment options, such as endocrine agents or HER2-directed therapy are unavailable, chemotherapy remains the mainstay of systemic treatment.
In a recent study of our institute, it was shown that TNBC frequently shows an array comparative genomic hybridization (aCGH) genomic profile that is also present in breast cancers of BRCA1 mutation carriers [2] . We have hypothesized that this profile is indicative of defects in the BRCA pathway, resulting in features that are often called 'BRCAness'. As the BRCA1 protein plays a crucial role in the DNA repair pathway of homologous recombination, it is assumed that tumors with BRCA1 dysfunction are homologous recombination deficient (HRD). In vitro and preclinical studies have shown that tumors with aberrations in the BRCA1 gene, resulting in HRD, are extremely sensitive to DNA double-strand break (DSB) inducing chemotherapy [3] [4] [5] . We have recently shown that tumors with an aCGH profile suggestive of BRCAness are extremely sensitive to high-dose platinum-based chemotherapy but have similar sensitivity to conventionally dosed chemotherapy or may even do worse than other triple-negative tumors with conventional therapy [2] .
To further investigate the clinical consequences of our assay for BRCAness, we studied a consecutive series of patients who presented for adjuvant chemotherapy of early TNBC in a community hospital. We sought to determine the proportion of TNBCs with BRCA1-like features and to identify possible correlations with clinical course and survival.
patients and methods patients
In the period of March 1995 to June 2010, 157 patients were diagnosed with a TNBC in the Deventer Hospital, Deventer, The Netherlands. Demographic, treatment and follow-up characteristics were collected for all these patients. Patients were included when they had received adjuvant chemotherapy that contained at least one bifunctional alkylating agent. These regimens were AC (doxorubicin and cyclophosphamide every 3 weeks or dose dense every 2 weeks), FEC (5-fluorouracil, epirubicin and cyclophosphamide every 3 weeks), TAC (docetaxel, doxorubicin and cyclophosphamide every 3 weeks) or CMF (cyclosphosphamide, methotrexate and 5-fluorouracil every 3 weeks).
histopathology Paraffin-embedded sections were immunohistochemically assessed as described previously [6] . All tissue sections were reviewed by a single pathologist (MMS) for histological classification and immunohistochemical (IHC) assessment. Estrogen receptor (ER) and progesterone receptor (PR) positivity was defined when at least 10% of the tumor cells stained positive for ER and PR, respectively. HER2 was scored on the HER2 IHC staining according to the standard criteria. The scores 0 and 1+ were considered negative. When the HER2 IHC staining scored 2+, a chromogenic in situ hybridization (CISH) was carried out to determine the HER2 amplification status. When the CISH showed no amplification, the tumor was considered HER2 negative. Only triple-negative tumors were included in this study. Hematoxylin-and eosin-stained slides were scored for tumor percentages. Tumor percentage had to be at least 50%, resulting in 103 tumors suitable for DNA isolation and multiplex ligation-dependent probe amplification (MLPA) analysis.
DNA isolation and MLPA
DNA was isolated from formalin-fixed paraffin-embedded tumor tissue, using NaSCN and purified with a DNeasy column (QIagen DNA extraction kit; Qiagen, Venlo, The Netherlands). MLPA was carried out to determine the relative copy number of various DNA sequences. The standard MLPA protocol, which was used here, has been described, in detail, elsewhere [7] . The MLPA method is based on sequence-specific probe hybridization to genomic DNA. In short, each MLPA probe consists of two target-specific oligonucleotides that are ligated after overnight hybridization. A universal primer pair (fluorescently labeled) is used to amplify all ligated probes by PCR. As one MLPA probe oligonucleotide contains a stuffer DNA sequence of a certain length, the amplifications products can be distinguished based on their specific size. The semi quantitative analysis of the PCR products is done by capillary electrophoresis. In this study, MLPA probemix P376-B1 detecting a BRCA1-like genomic profile was used (MRC-Holland, Amsterdam, The Netherlands) [8] . This MLPA probemix contains 34 target probes covering the most important genomic regions of the BRCA1-like classifier [9] . In addition, it contains eight control reference probes, which detect autosomal chromosomal locations, which are relatively quiet in breast cancer genomes.
MLPA data analysis
To automate the interpretation of the fragment analysis, the relative quantity of the amplified probes in each sample was determined using a template in Excel (Microsoft, Redmond, WA) [10] . For this purpose, the relative peak areas for each probe were calculated as fractions of the total sum of peak areas in a certain sample. Subsequently, the fraction of each peak was divided by the average peak fractions of the corresponding probe in control samples [Promega (female reference DNA), Madison, WI]. Data values from Excel for all the 34 target-specific probes were used for Prediction analysis for microarrays [11, 8] . A sample with a BRCA1-like score of ≥0.5 was classified as BRCA1-like, if the score was <0.5 the sample was called non-BRCA1-like [8] . MLPA failed for two samples, resulting in a total number of 101 cases successfully typed by MLPA.
statistics
Differences between the BRCA1-like group and the non-BRCA1-like group were evaluated by Fisher's exact test for categorical variables and t-test for continuous variables. Survival curves were made using the Kaplan-Meier method and were compared with the log-rank test. Hazard ratios (HRs) for the different confounders were calculated with a univariate Cox regression analysis. Relapse-free survival (RFS) was used as the dependent variable. The statistical analysis was carried out by using IBM SPSS Statistics 18 (Chicago, IL). Of the 157 selected patients with a triple-negative tumor, 101 patients were treated with conventional chemotherapy and had DNA of sufficient quality to assess the BRCA1-like profile by MLPA. All results are based on these 101 patients. The MLPA showed that 35 patients had a tumor with a non-BRCA1-like profile and 66 patients had a tumor with a BRCA1-like profile (Table 1) . Patients with a BRCA1-like tumor were younger than the patients in the non-BRCA1-like group, a difference that approached statistical significance (P = 0.06). There was no significant difference between the groups when compared for T stage (P = 0.35). In the non-BRCA1-like group, however, tumor-positive lymph nodes were found more often than in the BRCA1-like group (62% versus 38%, P = 0.03).
survival
The two patient groups, BRCA1-like and non-BRCA1-like, were well balanced in terms of surgery, radiation therapy and (neo)adjuvant chemotherapy. In addition, the chemotherapy regimens used were also not significantly different between the groups (Table 2) . For 101 patients, follow-up data were available; the median follow-up was 50 months (range 2-158 months) in this cohort. During this period, 22 patients experienced relapse (local or distant metastases) or died of TNBC. The RFS differed not significantly between both groups (P = 0.352; Figure 1A ). The 5-year RFS for the BRCA1-like group was 80% and that for the non-BRCA1-like group 75%. In total, 18 patients died of TNBC. The time to death from TNBC was shorter, although not significant, in the group with a non-BRCA1-like profile (P = 0.359; Figure 1B ). In total, 20 patients died in the study period. Also, overall survival was not different between the two groups (P = 0.414; Figure 1C ).
univariate survival analyses
Patients with a T3 or T4 tumor seemed to have an almost three times higher risk to develop a relapse or metastatic disease than patients with a smaller tumor (HR 2.95, 95% confidence interval 1.09-8.03, P = 0.03) ( Table 3 ). All the other variables, including the BRCA1-like profile, were not associated with survival. When we restricted the analysis to patients treated with anthracyclins, no difference in survival was noted (data not shown). Similarly, when the data were stratified for age at diagnosis, nodal status and radiotherapy, no significant differences were observed (data not shown).
discussion
In this study, the clinical characteristics and the effect of conventionally dosed adjuvant chemotherapy was studied in TNBC, depending on the presence or absence of a BRCA1-like 
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DNA profile. In a previous study by Vollebergh et al. [2] , it was found that BRCA1-like tumors were extremely sensitive to high-dose platinum-based alkylating chemotherapy, much more than to conventional-dose chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide. The latter chemotherapy also leads to double-strand DNA breaks during DNA replication. However, the study only contained 31 patients with TNBC who had received conventional chemotherapy, and all had high-risk disease with four or more axillary lymph node metastases. The characteristics of a larger series of early TNBC with a more common risk distribution appeared desirable to confirm and extend these findings. Therefore, we studied 101 TNBC patients who were treated with conventional-dose chemotherapy. A newly developed MLPA assay was used to test if the tumors had a BRCA1-like genomic profile, which was derived from the genomic profiles of BRCA1-mutated breast cancer [8] . This profile is assumed to represent BRCAness and thus is thought to be a marker for homologous recombination deficiency. Several studies have consistently shown that tumors with BRCAness are extremely sensitive to chemotherapy with DNA cross-linking agents that lead to double-strand DNA breaks during the S phase of the cell cycle, when homologous recombination is the dominant DSB repair mechanism [2, 12, 13] .
Our results show that over half of the early-stage TNBCs show a BRCA1-like profile consistent with a presumable homologous recombination defect. These patients, when treated with conventional-dose adjuvant chemotherapy, do not differ from patients with a non-BRCA1-like TNBC in terms of RFS. These findings confirm our previous results [2] . The patients with BRCA1-like tumors were younger than those with non-BRCA1-like tumors. This corresponds with the findings of Goffin et al. [14] in BRCA1-mutated tumors, showing that BRCA1-mutated tumors arise at an earlier age, as is to be expected in hereditary breast cancer [14] . Furthermore, it was hypothesized that BRCA1-like tumors might grow more aggressively as a result of the marked genetic instability caused by the DNA repair defect. This could include a higher growth rate and a higher tendency for dissemination through lymph or blood vessels. The T-stage can be considered as a derivative of the tumor growth rate. Our study shows, however, that the T-stage distribution was not different between BRCA1-like and non-BRCA1-like tumors. Regarding the lymph node metastases, the results show the opposite of what was expected. There is a remarkable difference between the groups when compared for nodal status. The BRCA1-like group shows a significantly higher number of patients without tumor-positive lymph nodes compared with the non-BRCA1-like group. Kriege et al. [15] found this difference as well in a study where BRCA1-mutated breast cancer patients were compared with non-BRCA1-like breast cancer patients [15] . Where does this difference come from? The study from Foulkes et al. [16] shows that patients with a BRCA1 related tumor do not have the correlation between tumor size and lymph node status, which other subtypes tend to have [16] . This indicates that triple-negative BRCA1-like tumors, as identified by the MLPA assay, differ significantly from triple-negative tumors without a BRCA1-like profile. We also investigated whether patients with BRCA1-like tumors have a different prognosis after conventional-dose chemotherapy with alkylating agents. The survival analysis does not show a difference between BRCA1-like and non-BRCA1-like tumors. Although the patient group is not very large and a minor difference in prognosis may have gone unnoticed, these findings are in line with results of Kriege et al. [15] . They compared the sensitivity to conventional chemotherapy for breast cancer in BRCA1 mutation carriers and in sporadic breast cancer patients and did not observe a significantly better prognosis after conventional chemotherapy in BRCA1-associated breast cancer. Rather, a trend for better response rate to conventional chemotherapy and a longer progression-free survival were observed [15] .
In our previous studies, we used aCGH to assess the BRCA1-like genomic profile [1, 2, 9] . We have recently shown that the MLPA method used in this study represents an attractive alternative for aCGH, as it is rapid easily standardized and therefore suitable for a clinical application [8] . Therefore, the MLPA method was used in this study. Both the MLPA and the aCGH test for homologous recombination proficiency in an indirect way: both determine whether the tumor has a specific combination of DNA gains and losses, i.e. seen in almost all BRCA1-mutated TNBCs. Some of the BRCA1-like tumors contain an inactivating BRCA1 mutation, some express only very low levels of BRCA1 messenger RNA [17] , gene expressing profiling [12] or promoter methylation and gene expression [13] . Another problem is suggested by findings of Swisher et al. [18] . They found in a group of BRCA1-mutated ovarian cancer patients that an additional BRCA1 mutation can restore the BRCA1 reading frame. In this way, the MLPA may show a BRCA1-like profile, while a functional BRCA1 protein is being produced as a result of reversion [18] . Most importantly, this study does not show survival difference between BRCA1-like and non-BRCA1-like tumors treated with conventional-dose chemotherapy with alkylating agents. However, we hypothesize that high-dose chemotherapy or the new class of targeted agents, the poly ADP ribose polymerase (PARP) inhibitors, may improve the survival in this specific subgroup if homologous recombination deficiency is indeed the cause of the DNA gains and losses profile. The treatment possibilities with PARP inhibitors should be exploited as encouraging results with PARP inhibitors have been reported for breast and ovarian cancer in BRCA1 mutation carriers [19] . Further research is needed to confirm these findings. Ultimately, this may result in an improved survival of TNBC patients by a better selection of patients requiring treatment targeting HRD.
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